TY - JOUR T1 - Effects of Single Nucleotide Polymorphisms on Treatment Outcomes and Toxicity in Patients Treated with Sunitinib JF - Anticancer Research JO - Anticancer Res SP - 4619 LP - 4626 VL - 33 IS - 10 AU - CHI HOON MAENG AU - JUN HO YI AU - JEEYUN LEE AU - JUNG YONG HONG AU - MOON KI CHOI AU - HYUN AE JUNG AU - JOON OH PARK AU - SE HOON PARK AU - YOUNG SUK PARK AU - WON KI KANG AU - HO YEONG LIM Y1 - 2013/10/01 UR - http://ar.iiarjournals.org/content/33/10/4619.abstract N2 - Background/Aim: We analyzed the efficacy and toxicity profile of sunitinib according to single nucleotide polymorphisms (SNPs) of vascular endothelial growth factor receptor (VEGFR) and Kinase insert domain receptor (KDR). Patients and Methods: We examined eight known SNPs of VEGFA and five SNPs of KDR among patients with gastric or biliary tract cancer who were treated with sunitinib. We retrospectively assessed clinical outcomes and their relationships to these SNPs. Results: A total of 63 patients were evaluable. Among candidate SNPs, rs2010963 and rs833068 of VEGFA, and rs1870377 of KDR were associated with poor time to treatment failure (TTF) (p=0.009, 0.002, and 0.029, respectively), while rs1870377 and rs7692791 of KDR were associated with poor overal survival (OS) (p=0.001 and 0.03, respectively). Multivariate analysis showed that only rs1870377 had significant effects on both TTF and OS. Toxicity evaluation indicated that rs1531289 of KDR was associated with grade 3-4 anemia. (p=0.021). Conclusion: Certain SNPs of KDR may affect treatment outcome and toxicity in patients treated with sunitinib. ER -